Guangzhou, China – On February 22 to 24, 2019, the CSI Asia-Pacific 2019 congress took place in Guangzhou, China. The congress gave a comprehensive review and outlook of major topics in the application and development of interventional therapy for congenital, structural and valvar heart disease and gathered over 400 healthcare professionals and researchers from across the world. MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow") presented at the congress the independently developed VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow®") and VitaFlow® II Transcatheter Aortic Valve and Recapturable Delivery System ("VitaFlow® II"), which drew huge attention.
On February 23 afternoon, MicroPort® CardioFlow presented in cooperation with the TAVR team of Zhongshan Hospital Affiliated to Fudan University a live case using VitaFlow® II. A TAV27 valve was chosen for this patient, and the procedure went quite successfully. After the valve deployment, the echocardiography and angiography showed that pressure gradient was 0mmHg with was no paravalvular leak and no aortic regurgitation. The procedure delivered outstanding clinical result. During the live case, the healthcare professionals present at the congress and the physicians in the operating room had heated discussions and they all agreed on the post-operative effectiveness of VitaFlow® II. During the congress, MicroPort® CardioFlow also had exchanges with healthcare professionals from all of the world on the current state of valvular disease treatment and the development of medical device technologies. The healthcare professionals highly recognized the significant efficacy and performance of MicroPort® CardioFlow’s VitaFlow® for bicuspid ASS patients.
MicroPort® CardioFlow’s VitaFlow® II inherits the unique motorized handle design of VitaFlow®. It can be completely recaptured before 75% deployment. The reinforced inner and outer shafts still retain flexibility and can be bent 360 degrees. The product also innovatively introduces the integrated sheath to widen the range of the sizes of access artery and effectively reduces the incidence rate of vascular complications. In addition, VitaFlow® II is accompanied with balloon dilation catheter and introducer set to provide the patients suffering severe aortic stenosis and doctors with a comprehensive integrated therapeutic solution. As a result, the safety and efficacy of the procedure are increased. Thus far, the product has successfully applied for and entered the special review and approval procedure for innovative medical devices with the National Medical Products Administration (NMPA), known as the Green Path, which is expected to reduce its time to market and benefit more domestic patients suffering severe aortic stenosis as soon as possible.